Media headlines about Ekso Bionics (NASDAQ:EKSO) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ekso Bionics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.3568088554653 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Ekso Bionics (NASDAQ:EKSO) remained flat at $$2.13 during mid-day trading on Friday. 399,643 shares of the stock were exchanged, compared to its average volume of 1,885,689. The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18. Ekso Bionics has a 12-month low of $0.99 and a 12-month high of $4.77. The company has a market capitalization of $127.60, a PE ratio of -1.88 and a beta of -0.07.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $2.40 million. Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%. analysts anticipate that Ekso Bionics will post -0.81 earnings per share for the current fiscal year.

EKSO has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Ekso Bionics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research note on Thursday, September 7th. ValuEngine raised shares of Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th.

In other news, insider Russ Angold sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total value of $175,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.32% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Insider Buying and Selling by Quarter for Ekso Bionics (NASDAQ:EKSO)

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with's FREE daily email newsletter.